Compositions of low dose psilocin and use of same in treatment of als

Low-dose psilocin administration, stabilized and monitored for side effects, addresses the limitations of current ALS treatments by providing therapeutic benefits with minimal adverse effects and improved stability.

WO2026234672A1PCT designated stage Publication Date: 2026-11-12HAIM PHARMA GROUP LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2026/050381
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current therapeutic options for ALS are limited in effectively addressing neurodegenerative processes, and existing psychedelic compounds face challenges with dosing, tolerability, chemical stability, and patient selection, while monitoring disease progression and therapeutic response remains an evolving area.

Method used

Administration of low-dose psilocin ranging from 0.01 mg to 10 mg, formulated with stabilization techniques such as encapsulation and co-formulation with antioxidants, and monitored for side effects to optimize therapeutic benefit.

Benefits of technology

Low-dose psilocin provides therapeutic benefits in ameliorating ALS symptoms with minimal adverse effects, maintaining stability over extended periods, and enabling personalized dosing adjustments based on individual response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IL2026050381_12112026_PF_FP_ABST
    Figure IL2026050381_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention is directed to a method for ameliorating at least one symptom of Amyotrophic Lateral Sclerosis (ALS) in a subject afflicted therewith, including orally administering to the subject psilocin at a daily dose ranging between 0.01 mg and 10 mg. Further provided is an oral pharmaceutical composition including psilocin formulated for use at a daily dose ranging between 0.01 mg and 10 mg of psilocin.
Need to check novelty before this filing date? Find Prior Art

Description

COMPOSITIONS OF LOW DOSE PSILOCIN AND USE OF SAME IN TREATMENT OF ALSCROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority of U.S. Provisional Patent Application No.63 / 800,552, titled "COMPOSITIONS AND METHODS FOR TREATING ALS VIA PSILOCIN-INDUCED NEUROPROTECTION AND NEUROPLASTICITY", filed May 6, 2025, the contents of which are incorporated herein by reference in their entirety.FIELD OF INVENTION

[0002] The present disclosure relates to neurology and pharmaceutical sciences, and more particularly to methods and compositions for treating amyotrophic lateral sclerosis (ALS) and related neurodegenerative conditions through administration of low-dose formulations of psilocin.BACKGROUND

[0003] Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons in the brain and spinal cord. The disease leads to progressive muscle weakness, paralysis, and respiratory failure. ALS affects tens of thousands of individuals worldwide, with most patients surviving only a few years following diagnosis.

[0004] The pathophysiology of ALS involves multiple interconnected mechanisms, including glutamate-mediated excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, and neuroinflammation. Motor neurons in ALS patients exhibit elevated calcium levels and increased susceptibility to glutamate toxicity. Additionally, microglial activation and elevated inflammatory markers such as Tumor Necrosis Factor Alpha (TNF-a) and Interleukin-6 (IL-6) contribute to disease progression. Reduced neurotrophic factor signaling, including diminished brain-derived neurotrophic factor (BDNF) activity and Tropomyosin Receptor Kinase B (TrkB) receptor activation, further compromises neuronal survival and plasticity.

[0005] Current therapeutic options for ALS remain limited. Existing approved treatments provide modest benefits in slowing disease progression or extending survival, but do not halt or reversemotor neuron degeneration. Many patients continue to experience progressive functional decline despite available therapies. The development of disease-modifying treatments that address the underlying neurodegenerative processes remains an area of active research.

[0006] Serotonergic signaling pathways have been implicated in neuronal health and plasticity. Compounds that modulate serotonin receptors, particularly the 5-Hydroxytryptamine Receptor 2A (5-HT2A) receptor subtype, may influence neurotrophic signaling, synaptic plasticity, and inflammatory responses. However, many psychoactive compounds that interact with serotonergic systems present challenges related to dosing, tolerability, chemical stability, and patient selection.

[0007] Formulation stability represents a technical challenge for certain pharmacologically active compounds that are susceptible to oxidative degradation. Maintaining consistent pharmacological activity over extended storage periods may require specialized stabilization techniques and packaging approaches.

[0008] Monitoring disease progression and therapeutic response in ALS presents additional challenges. Biomarkers such as neurofilament light chain (NfL) levels and functional assessments such as the ALS Functional Rating Scale-Revised (ALSFRS-R) are used to track disease status, but integrating these measures into personalized treatment approaches remains an evolving area.

[0009] Accordingly, there exists a desire for improved compositions and methods for treating ALS and related neurodegenerative conditions.SUMMARY

[0010] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0011] The present invention, in some embodiments, is based, at least in part, on the surprising finding of a pilot study conducted in rodents, showing that psilocin was significantly more potent than expected, with 5-Hydroxytryptamine Receptor 2A (5-HT2A) engagement at 0.03 mg, where the state of the art relates to 3 mg as a borderline engagement level. Published human doseresponse studies with psilocybin identify approximately 45 pg / kg psilocybin, corresponding to about 3 mg psilocybin in a 70 kg adult, as a very-low-dose exposure level. On a molar basis, thiscorresponds to approximately 2.2 mg psilocin equivalent. The proposed low-dose psilocin range is therefore positioned below established very-low-dose psychedelic exposure levels while enabling controlled chronic administration.

[0012] According to the first aspect, there is provided a method for ameliorating at least one symptom of Amyotrophic Lateral Sclerosis (ALS) in a subject afflicted therewith, the method comprising orally administering to the subject psilocin at a daily dose ranging between 0.01 mg and 10 mg.

[0013] According to another aspect, there is provided a method for ameliorating at least one symptom of ALS in a subject afflicted therewith, the method comprising the steps: (a) orally administering to the subject psilocin at a daily dose ranging between 0.01 mg and 10 mg; (b) monitoring appearance of at least one side effect selected from the group consisting of: suicidal ideation, cardiovascular manifestation, hallucination, impaired daily ability to operate, serotonin syndrome, and any combination thereof, in the subject; and (c) adjusting the daily dose based on the results of the monitoring.

[0014] According to another aspect, there is provided an oral pharmaceutical composition comprising psilocin for use at a daily dose ranging between 0.01 mg and 10 mg of psilocin in the amelioration of at least one symptom of ALS in a subject afflicted therewith.

[0015] In some embodiments, the psilocin is in a composition further comprising a pharmaceutically acceptable carrier. In some embodiments, the psilocin is formulated using a stabilization technique selected from the group consisting of: encapsulation, co-formulation with an antioxidant, or both. In some embodiments, the antioxidant comprises ascorbic acid, ethylenediaminetetraacetic acid (EDTA), N-acetylcysteine (NAC), glutathione, cysteine, sodium metabisulfite, sodium bisulfite, tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, or any combination thereof.

[0016] In some embodiments, the method further comprises a step comprising monitoring the subject after the administering. In some embodiments, the monitoring comprises determining appearance of at least one side effect selected from the group consisting of: Suicidal ideation, cardiovascular manifestation, hallucination, impaired daily ability to operate, serotonin syndrome, and any combination thereof, in the subject.

[0017] In some embodiments, the lack of appearance of at least one side effect indicates that the subject is responding to the administering, thereby repeating the administering. In some embodiments, the repeating comprises repeatedly administering the dose of psilocin or an increased dose of the psilocin. In some embodiments, the appearance of the at least one side effect indicates that the subject is adversely responding to the administering, thereby reducing the dose of the psilocin or ceasing the administering. In some embodiments, the daily dose of the psilocin induces less adverse effects compared to a standard control dose of psilocin. In some embodiments, the adverse effects are determined by a validated side effect scale.

[0018] In some embodiments, the method further comprises a step before the administering, comprising diagnosing the subject with ALS. In some embodiments, the subject is not afflicted with schizophrenia, bipolar disorder, active substance use disorder, or any combination thereof. In some embodiments, the subject is not concurrently using a monoamine oxidase inhibitor (MAOI) or a selective serotonin reuptake inhibitor (SSRI).

[0019] In some embodiments, the composition further comprises an enteric coat. In some embodiments, the psilocin is encapsulated within the enteric coat. In some embodiments, the composition is formulated for controlled release. In some embodiments, the controlled release is pH-controlled release. In some embodiments, the adjusting is increasing or decreasing. In some embodiments, the monitoring further comprises determining at least one of: neurofdament light chain (NfL) levels, motor function assessment using the ALS Functional Rating Scale-Revised (ALSFRS-R), or both, in the subject or a in sample obtained or derived therefrom. In some embodiments, the reduction in the levels of the NfL compared to a control, indicates that the subject is responding to the administering, thereby repeating the administering. In some embodiments, the maintenance or increase in the levels of the NfL compared to a control, indicates that the subject is not responding to the administering, thereby ceasing the administering.

[0020] In some embodiments, the oral pharmaceutical composition further comprises at least one stabilizing agent selected from the group consisting of: an antioxidant, an oxygen scavenger, a moisture-absorbing agent, and any combination thereof. In some embodiments, the oral pharmaceutical composition is in a form selected from the group consisting of: a tablet, a capsule, a suspension, a sublingual film, a buccal film, and a spray. In some embodiments, the oral pharmaceutical composition further comprises a carrier selected from the group consisting of:cyclodextrin, lipid nanoparticle, phospholipid vesicle, and lecithin-based emulsion. In some embodiments, the oral pharmaceutical composition further comprises an enteric coat. In some embodiments, the oral pharmaceutical composition is characterized by being stable for at least six months at room temperature.

[0021] Unless otherwise defined, all technical and / or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and / or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

[0022] Further embodiments and the full scope of applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.BRIEF DESCRIPTION OF FIGURES

[0023] Non-limiting and non-exhaustive examples are described with reference to the following figures.

[0024] Fig. 1 includes a graph showing the mean velocity while moving in the light phase (L) of vehicle-treated SodlfWT) larvae (Gl), vehicle-treated Sodl(G93R) larvae (G2), and Sodl(G93R) larvae treated with psilocin at 0.1 pM (G3), 0.2 pM (G4), and 20 pM (G5). Data show the mean ± SEM as the fold change with respect to the unaffected control Sodl(WT) larvae (Gl). The N at the bottom of each bar specifies the number of larvae included in the data analysis of each experimental group. Statistical differences (Kruskal-Wallis test followed by Dunn’s test) are represented by *p < 0.05 and **p < 0.01, while “ns” indicates no significant differences (p > 0.05).

[0025] Fig. 2 includes a graph showing the maximum velocity in the dark phase (D) of vehicle-treated SodlfWT) larvae (Gl), vehicle-treated Sodl(G93R) larvae (G2), and Sodl(G93R) larvaetreated with psilocin at 0.1 pM (G3), 0.2 pM (G4), and 20 pM (G5). Data show the mean ± SEM as the fold change with respect to the unaffected control Sodl(WT) larvae (Gl). The N at the bottom of each bar specifies the number of larvae included in the data analysis of each experimental group. Statistical differences (Kruskal-Wallis test followed by Dunn’s test) are represented by *p < 0.05, **p < 0.01, ***p < 0.001; exact p value show is given when 0.05 < p < 0.1; while “ns” indicates no significant differences (p > 0.05).DETAILED DESCRIPTION

[0026] The following description sets forth exemplary embodiments of the present disclosure. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure. Rather, the description also encompasses combinations and modifications to those exemplary embodiments described herein.

[0027] According to the first aspect, there is provided a method for treating or ameliorating at least one symptom of a neurodegenerative disease in a subject afflicted therewith, comprising administering to the subject a low dose psilocin.

[0028] As used herein, the term "neurodegenerative disease" refers to a group of disorders characterized by progressive degeneration and loss of neurons in the central nervous system or peripheral nervous system, leading to impairments in motor function, cognitive function, or both. Neurodegenerative diseases may involve multiple pathophysiological mechanisms including protein aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, and excitotoxicity. Examples of neurodegenerative diseases include, but are not limited to, Amyotrophic Lateral Sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, Frontotemporal Dementia (FTD)„ progressive supranuclear palsy, corticobasal degeneration, and spinal muscular atrophy. Each possibility represents a separate embodiment of the invention.

[0029] In some embodiments, a neurodegenerative disease is selected from: ALS, Parkinson’s disease, FTD, and any combination thereof.

[0030] According to another aspect, there is provided a method for ameliorating at least one symptom of ALS in a subject afflicted therewith, comprising administering to the subject a low dose psilocin.

[0031] In some embodiments, the method comprises orally administering to a subject psilocin at a daily dose ranging between 0.01 mg and 10 mg. In some embodiments, the psilocin is in a composition further comprising a pharmaceutically acceptable carrier. The present disclosure, in some embodiments, also encompasses an oral pharmaceutical composition comprising psilocin for use at a daily dose ranging between 0.01 mg and 10 mg of psilocin in the amelioration of at least one symptom of ALS in a subject afflicted therewith.

[0032] As used herein, the term "psilocin" refers to 4-hydroxy-N,N-dimethyltryptamine (CAS 520-53-6), a tryptamine compound that acts as an agonist at serotonin receptors, including the 5-HT2A receptor subtype. Psilocin is the pharmacologically active metabolite of psilocybin and exhibits direct receptor binding without requiring metabolic conversion. Psilocin modulates serotonergic signaling in cortical and subcortical structures and directly or indirectly activates TrkB receptors, thereby promoting brain-derived neurotrophic factor (BDNF) signaling cascades.

[0033] As used herein, the term "low dose psilocin" refers to a daily dose of psilocin ranging between 0.01 mg and 10 mg, which is below the threshold typically associated with perceptual disturbances or psychoactive effects. Low dose psilocin provides therapeutic benefit while minimizing adverse effects associated with higher doses. As demonstrated in the zebrafish studies described herein, efficacy was observed at low concentrations (0.1 pM) while higher concentrations showed diminishing or no additional benefit, suggesting an optimal therapeutic window at low doses. In some embodiments, “low” is compared to a control standard dose of psilocin.

[0034] In some embodiments, psilocin comprises a precursor of psilocin. In some embodiments, psilocin comprises a metabolite of psilocin.

[0035] In some embodiments, the active agent is not psilocybin.

[0036] In some embodiments, the psilocin comprises synthetic psilocin.

[0037] As used herein, the term "ALS" or "Amyotrophic Lateral Sclerosis" refers to a progressive neurodegenerative disease characterized by the degeneration of motor neurons in the brain and spinal cord. ALS leads to progressive muscle weakness, paralysis, and respiratory failure. The pathophysiology of ALS involves multiple interconnected mechanisms, including glutamate-mediated excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, and neuroinflammation.

[0038] As used herein, the term "ameliorating" refers to reducing, alleviating, mitigating, or improving at least one symptom or manifestation associated with ALS. Ameliorating includes, but is not limited to, improving neuronal viability, reducing neuroinflammation, preserving motor function, modulating motor behavior, or slowing disease progression.

[0039] In some embodiments, ameliorating at least one symptom of ALS comprises treating ALS.

[0040] As used herein, the term "subject" refers to a mammal, including a human, afflicted with ALS or at risk of developing ALS. In some embodiments, the subject is a human patient who has received a confirmed diagnosis of ALS using clinical and laboratory criteria, such as electromyography (EMG), magnetic resonance imaging (MRI), and biomarker evaluation.

[0041] As used herein, the term "pharmaceutically acceptable carrier" refers to a substance or combination of substances that are included in a pharmaceutical composition to facilitate administration, improve stability, enhance bioavailability, or provide other functional benefits without causing unacceptable adverse effects in the subject. Pharmaceutically acceptable carriers may include, but are not limited to, cyclodextrins, lipid nanoparticles, phospholipid vesicles, lecithin-based emulsions, polymer-based matrices, stabilizers, bulking agents, and excipients.

[0042] As used herein, the term "daily dose" refers to the total amount of psilocin administered to a subject within a 24-hour period. The daily dose is administered as a single dose or divided into multiple doses throughout the day.

[0043] As used herein, the term "symptom" in the context of ALS refers to any clinical manifestation or functional impairment associated with the disease, including but not limited to motor deficits, muscle weakness, spasticity, respiratory impairment, dysphagia, and changes in locomotor activity or motor behavior.

[0044] In various embodiments, the daily dose of psilocin ranges between 0.01 mg and 10 mg. In some embodiments, the daily dose ranges between 0.01 mg and 5 mg. In some embodiments, the daily dose ranges between 2 mg and 8 mg. In some embodiments, the daily dose ranges between 3 mg and 7 mg. In some embodiments, the daily dose ranges between 5 mg and 10 mg. Each possibility represents a separate embodiment of the invention. In various embodiments, the dailydose of psilocin ranges between 0.01 mg and 1 mg, 0.05 mg and 1 mg, 0.01 mg and 3 mg, 0.07 mg and 0.9 mg, 0.03 mg and 0.5 mg, and 0.05 mg and 0.3 mg, 0.01 mg and 1 mg. Each possibility represents a separate embodiment of the invention.

[0045] In some embodiments, the daily dose of psilocin ranges from 0.01 mg to 10 mg, including any subrange therein, with subranges including ultra-low, low, and intermediate dose ranges selected to support chronic administration while reducing the likelihood of perceptual or functional impairment.

[0046] Psilocin is susceptible to oxidative degradation, and maintaining consistent pharmacological activity over extended storage periods requires specialized stabilization techniques. In various embodiments, psilocin is formulated using a stabilization technique selected from the group consisting of: encapsulation, co-formulation with an antioxidant, lyophilization, or any combination thereof.

[0047] As used herein, the term "encapsulation" refers to a process in which psilocin is enclosed within a protective coating or matrix material to shield the compound from environmental factors such as oxygen, light, and moisture. Encapsulation involves polymeric carriers that form a barrier around psilocin particles, thereby reducing exposure to degradation-inducing conditions. In some embodiments, a microencapsulated psilocin compound is protected from degradation by exposure to light or oxygen. In some embodiments, encapsulation is or comprises microencapsulation.

[0048] As used herein, the term "co-formulation with an antioxidant" refers to the inclusion of one or more antioxidant compounds in a psilocin formulation to prevent or reduce oxidative degradation. In various embodiments, the antioxidant comprises: ascorbic acid, ethylenediaminetetraacetic acid (EDTA), N-acetylcysteine (NAC), glutathione, cysteine, sodium metabisulfite, sodium bisulfite, tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, or any combination thereof, or any combination thereof. Ascorbic acid functions as a reducing agent that scavenges reactive oxygen species, while EDTA chelates metal ions that catalyze oxidation reactions. In some embodiments, both ascorbic acid and EDTA are included in a single formulation to provide complementary stabilization mechanisms. In some embodiments, combinations of multiple antioxidant compounds are included in a single formulation to provide complementary stabilization mechanisms.

[0049] As used herein, the term "lyophilization" refers to a freeze-drying process in which water is removed from a psilocin formulation under reduced pressure and low temperature conditions. Lyophilization produces a dry, stable product with reduced susceptibility to hydrolytic and oxidative degradation. Lyophilized psilocin formulations are reconstituted prior to administration or are formulated into solid dosage forms.

[0050] In some embodiments, psilocin formulations employ combinations of stabilization techniques. For example, a psilocin formulation is microencapsulated and co-formulated with an antioxidant. In other embodiments, a lyophilized psilocin formulation includes antioxidants such as ascorbic acid or EDTA. Each combination represents a separate embodiment.

[0051] In various embodiments, psilocin formulations include additional stabilizing agents. In some embodiments, the psilocin formulation comprises at least one stabilizing agent selected from the group consisting of: an antioxidant, an oxygen scavenger, a moisture-absorbing agent, and any combination thereof. Oxygen scavengers are incorporated into packaging materials or included as separate components within the packaging to reduce oxygen exposure during storage.

[0052] In various embodiments, psilocin formulations contain polymer-based matrices as stabilizers. In some embodiments, the polymer-based matrix comprises polyvinyl alcohol. Polymer-based matrices provide structural support for the formulation and may contribute to controlled release characteristics. In some embodiments, psilocin formulations contain bulking agents such as trehalose or mannitol. Bulking agents provide structural integrity to lyophilized formulations and may contribute to the stability of the dried product.

[0053] In various embodiments, oral pharmaceutical compositions comprising psilocin further comprise at least one stabilizing agent selected from: an antioxidant, an oxygen scavenger, a moisture-absorbing agent, and any combination thereof. The inclusion of stabilizing agents may protect psilocin from degradation during storage and distribution.

[0054] As used herein, the term "antioxidant" refers to a compound that prevents or reduces oxidative degradation of psilocin by scavenging reactive oxygen species or chelating metal ions that may catalyze oxidation reactions. In various embodiments, antioxidants include ascorbic acid, ethylenediaminetetraacetic acid (EDTA), or combinations thereof. Ascorbic acid may function as a reducing agent that scavenges reactive oxygen species, while EDTA may chelate metal ions thatcatalyze oxidation reactions. In some embodiments, both ascorbic acid and EDTA may be included in a single formulation to provide complementary stabilization mechanisms.

[0055] As used herein, the term "oxygen scavenger" refers to a substance that absorbs or reacts with oxygen to reduce oxygen concentration in the environment surrounding the psilocin formulation. Oxygen scavengers may be incorporated into packaging materials or included as separate components within the packaging to reduce oxygen exposure during storage. In some embodiments, oxygen scavengers may be combined with oxygen-impermeable blister packaging to provide enhanced protection against oxidative degradation.

[0056] As used herein, the term "moisture-absorbing agent" refers to a substance that absorbs water or water vapor from the environment surrounding the psilocin formulation. Moistureabsorbing agents may reduce hydrolytic degradation of psilocin by maintaining a low-humidity environment within the packaging. In some embodiments, moisture-absorbing agents may be incorporated into packaging materials or included as desiccant packets within the packaging.

[0057] In various embodiments, oral pharmaceutical compositions include combinations of stabilizing agents. For example, an oral pharmaceutical composition may comprise an antioxidant and an oxygen scavenger. In other embodiments, an oral pharmaceutical composition comprises an antioxidant and a moisture-absorbing agent. In another embodiments, an oral pharmaceutical composition comprises an antioxidant, an oxygen scavenger, and a moisture-absorbing agent. Each combination represents a separate embodiment.

[0058] In some embodiments, oral pharmaceutical composition comprising psilocin is characterized by stability for at least six months at room temperature. In some embodiments, oral pharmaceutical composition remains stable for at least twelve months at room temperature. Stability may be confirmed by standard ICH (International Council for Harmonisation) stability testing conditions. ICH stability testing conditions may include storage at controlled temperature and humidity levels over defined time intervals, with periodic assessment of chemical purity, potency, and physical characteristics of the formulation. In some embodiments, the psilocin formulation remains chemically stable for at least twelve months at a suitable storage temperature as confirmed by standard ICH stability testing conditions.

[0059] As used herein, the term "chemically stable" refers to a psilocin formulation that maintains its chemical integrity, potency, and purity over a defined storage period under specified conditions.A chemically stable formulation may exhibit minimal degradation, oxidation, or formation of degradation products, and may retain at least 90% of its initial psilocin content over the storage period.

[0060] In some embodiments, stability of oral pharmaceutical composition is assessed by measuring psilocin content, degradation products, and physical appearance at defined time points during storage. A formulation may be considered stable when psilocin content remains within acceptable limits and degradation products remain below specified thresholds throughout the storage period. The shelf-life extension afforded by stabilization strategies may enhance usability for outpatient and remote care settings.

[0061] In some embodiments, oral pharmaceutical composition comprising psilocin is formulated in a form selected from: a tablet, a capsule, a suspension, a sublingual film, a buccal film, and a spray. Each dosage form may incorporate stability-enhancing excipients to prevent degradation due to oxygen, moisture, or light.

[0062] In some embodiments, psilocin is formulated as a tablet. Tablets may be prepared using compression techniques and may include binders, disintegrants, and lubricants in addition to stabilizing agents. In some embodiments, psilocin is formulated as a capsule. Capsules may comprise hard gelatin or vegetarian capsule shells containing psilocin in combination with antioxidants and fillers. In some embodiments, psilocin is formulated as a suspension. Liquid oral suspensions may contain psilocin dispersed in an aqueous or non-aqueous vehicle with suspending agents and stabilizers.

[0063] In some embodiments, psilocin is formulated as a sublingual film. Sublingual films may be designed for rapid onset via mucosal absorption. Sublingual films may provide rapid absorption while bypassing first-pass metabolism, which may result in faster onset of pharmacological activity compared to oral tablets or capsules. In some embodiments, psilocin is formulated as a buccal film. Buccal films may be applied to the inner cheek mucosa and may provide absorption characteristics similar to sublingual films.

[0064] In some embodiments, psilocin is formulated as a spray. Spray formulations may include oral sprays or oromucosal sprays that deliver psilocin to mucosal surfaces for absorption.

[0065] In some embodiments, an oral pharmaceutical composition comprising psilocin further comprises an enteric coat. As used herein, the term "enteric coat" refers to a coating that resists dissolution in the acidic environment of the stomach but dissolves in the more alkaline environment of the small intestine. Enteric coating may protect psilocin from gastric degradation and may reduce gastric irritation.

[0066] In some embodiments, the composition is encapsulated by the enteric coat. Enteric-coated capsules or tablets may deliver psilocin to the small intestine for absorption, thereby bypassing the acidic gastric environment.

[0067] In some embodiments, psilocin, the composition including same, or both, is formulated for slow release or controlled release. As used herein, the term "slow release" refers to a formulation designed to release psilocin gradually over an extended period. As used herein, the term "controlled release" refers to a formulation designed to release psilocin at a predetermined rate or in response to specific conditions. Controlled release formulations may provide sustained plasma concentrations of psilocin over an extended period. Slow release or controlled release formulations may reduce dosing frequency and may improve patient compliance.

[0068] In some embodiments, psilocin is formulated using encapsulation systems. As used herein, the term "encapsulation" refers to a process in which psilocin is enclosed within a protective shell or coating material. Encapsulation systems may protect psilocin from environmental degradation and may provide controlled release characteristics.

[0069] In some embodiments, psilocin is loaded into a matrix. As used herein, the term "matrix loading" refers to a formulation approach in which psilocin is dispersed or dissolved within a carrier matrix. In some embodiments, psilocin is formulated using polymeric matrix loading, in which psilocin is dispersed or dissolved within a polymer matrix. Polymeric matrix loading may provide sustained release of psilocin over an extended period.

[0070] In some embodiments, psilocin is formulated as a solid dispersion. As used herein, the term "solid dispersion" refers to a formulation in which psilocin is dispersed in a solid carrier matrix. In some embodiments, psilocin is formulated as an amorphous solid dispersion, in which psilocin is dispersed in an amorphous state within a carrier matrix. Amorphous solid dispersions may improve solubility and dissolution rate of psilocin compared to crystalline forms.

[0071] In some embodiments, psilocin is formulated as a spray-dried dispersion. As used herein, the term "spray-dried dispersion" refers to a formulation prepared by atomizing a solution or suspension containing psilocin and a carrier, followed by rapid drying to form particles. Spray-dried dispersions may enhance the dissolution rate and bioavailability of psilocin.

[0072] In some embodiments, psilocin is adsorbed or loaded onto a porous carrier. As used herein, the term "porous carrier" refers to a material having a high surface area due to the presence of pores or channels. Adsorption or loading of psilocin onto a porous carrier may increase surface area and improve dissolution characteristics.

[0073] In some embodiments, psilocin is formulated as multiparticulate systems. As used herein, the term "multiparticulate systems" refers to formulations comprising multiple discrete units, including but not limited to beads, pellets, granules, and microparticles. Multiparticulate systems may provide flexible dosing and modified release characteristics. Each possibility represents a separate embodiment of the invention.

[0074] In some embodiments, psilocin is formulated using lipid-based systems. Lipid-based systems may include, but are not limited to, lipid nanoparticles, liposomes, phospholipid vesicles, and emulsions. Lipid-based systems may enhance bioavailability of psilocin and may protect against oxidative degradation. Each possibility represents a separate embodiment of the invention.

[0075] In some embodiments, psilocin is formulated as inclusion complexes. As used herein, the term "inclusion complex" refers to a molecular association in which psilocin is encapsulated within the cavity of a host molecule. In some embodiments, psilocin is formulated as cyclodextrin complexes, in which psilocin is encapsulated within the hydrophobic cavity of a cyclodextrin molecule. Cyclodextrin complexes may improve aqueous solubility and stability of psilocin. Each possibility represents a separate embodiment of the invention.

[0076] In some embodiments, oral pharmaceutical composition comprising psilocin further comprises a carrier selected from: cyclodextrin, lipid nanoparticle, phospholipid vesicle, and lecithin-based emulsion. These carriers may facilitate drug solubilization, protect against oxidation, and promote mucosal absorption.

[0077] In some embodiments, the psilocin formulation comprises cyclodextrin as a carrier. Cyclodextrins are cyclic oligosaccharides that may form inclusion complexes with psilocin,thereby improving aqueous solubility and protecting psilocin from oxidative degradation. In some embodiments, the psilocin formulation comprises a lipid nanoparticle as a carrier. Lipid nanoparticles may encapsulate psilocin within a lipid matrix, providing protection from environmental degradation and enhancing bioavailability. In some embodiments, the psilocin formulation comprises a phospholipid vesicle as a carrier. Phospholipid vesicles, including liposomes, may encapsulate psilocin and facilitate transport across mucosal membranes. In some embodiments, the psilocin formulation comprises a lecithin-based emulsion as a carrier. Lecithinbased emulsions may improve the dispersion and absorption of psilocin in aqueous environments.

[0078] The pharmaceutical carriers described above may maintain chemical stability of psilocin and improve mucosal bioavailability across various delivery routes. In some embodiments, combination of carriers is employed in a single formulation to provide complementary benefits.

[0079] In addition to oral dosage forms, psilocin may be formulated for alternative routes of administration.

[0080] Each formulation described herein may incorporate stability-enhancing excipients and carriers as described previously to prevent degradation and maintain pharmacological activity during storage and administration.

[0081] In some embodiments, the method described herein further comprises a step comprising monitoring a subject after administering psilocin. Monitoring may enable assessment of therapeutic efficacy and may facilitate adaptive dosing based on individualized patient response.

[0082] In some embodiments, monitoring is for a period of at least 2 months, 3 months, 4 months, 6 months, 8 months, or any value and range therebetween. In some embodiments, monitoring is for a period ranging between 2 and 10 months, 3 and 10 months, 4 and 10 months, 6 and 12 months, and 8 and 16 months. Each possibility represents a separate embodiment of the invention.

[0083] As used herein, the term "neurofilament light chain" or "NfL" refers to a neuronal cytoskeletal protein that is released into blood or cerebrospinal fluid upon neuronal damage or degeneration. NfL concentrations in blood or cerebrospinal fluid may serve as a biochemical marker of neurodegeneration and may be used to track disease progression and therapeutic response in subjects with ALS.

[0084] As used herein, the term "ALS Functional Rating Scale-Revised" or "ALSFRS-R" refers to a validated clinical assessment instrument used to evaluate motor function in subjects with ALS. The ALSFRS-R may assess multiple functional domains including speech, salivation, swallowing, handwriting, cutting food, dressing and hygiene, turning in bed, walking, climbing stairs, and respiratory function. ALSFRS-R scores may be used to track disease progression and therapeutic response over time.

[0085] In some embodiments, monitoring comprises determining at least one of: neurofdament light chain (NIL) levels, motor function assessment using the ALS Functional Rating Scale-Revised (ALSFRS-R), or both, in a subject or a sample obtained or derived therefrom. In some embodiments, monitoring includes blood sampling for NIL levels at baseline and at regular intervals. In some embodiments, monitoring includes functional tracking using the ALSFRS-R at defined time points during treatment. In some embodiments, determining in a sample is an in vitro method. In some embodiments, the method is an in vitro method and comprises determining in a sample.

[0086] In some embodiments, therapeutic response is monitored using digital health monitoring tools.

[0087] In some embodiments, digital monitoring platforms may provide continuous or periodic data on patient mobility, speech, or respiratory function. In some embodiments, digital health metrics derived from mobile applications or wearable technologies may be used in combination with biochemical markers and clinical assessments to evaluate therapeutic efficacy.

[0088] In some embodiments, platelet serotonin levels is used as a biomarker for tracking treatment efficacy. In some embodiments, 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, is measured to assess serotonergic activity and treatment response. As used herein, the term "5-HIAA" refers to 5-hydroxyindoleacetic acid, a metabolite produced from the breakdown of serotonin. Platelet serotonin levels and 5-HIAA concentrations may provide information regarding serotonergic pathway engagement following psilocin administration.

[0089] In some embodiments, treatment response is defined as a statistically significant reduction in NIL concentration and / or stabilization or improvement in ALSFRS-R scores over a defined monitoring interval. In some embodiments, the monitoring interval extends for a duration of at least three months, which corresponds to standard evaluation intervals in clinical neurology trialsfor progressive motor disorders. In some embodiments, a reduction in NfL levels compared to baseline indicates that a subject is responding to treatment. In some embodiments, stabilization of ALSFRS-R scores, indicating a slowing of functional decline, indicates therapeutic benefit. In some embodiments, improvement in ALSFRS-R scores indicates therapeutic benefit.

[0090] In some embodiments, maintenance or increase in NfL levels compared to baseline indicates that a subject is non-responding to treatment. In some embodiments, maintenance or dis-improvement in ALSFRS-R scores indicates lack of therapeutic benefit.

[0091] In some embodiments, reduction, maintenance, or reduction of Nfl levels are compared to a baseline, wherein the baseline comprises the subject before administration according to the method of the invention, or a sample derived or obtained therefrom (e.g., before administration according to the method of the invention).

[0092] In some embodiments, monitoring schedules enable early detection of therapeutic efficacy and adaptive dosing based on individualized patient response. In some embodiments, longitudinal monitoring of NfL levels and ALSFRS-R scores are used to adjust treatment parameters over time.

[0093] In some embodiments, treatment response is assessed by comparing neurofilament light chain (NfL) levels obtained during treatment to a control value. As described above, NfL concentrations in blood or cerebrospinal fluid may serve as a biochemical marker of neurodegeneration. In some embodiments, a reduction in NfL levels compared to a control indicates that the subject is responding to administration of psilocin. In some embodiments, the administering is repeated to continue therapeutic benefit. The control may comprise a baseline NfL level obtained from the subject prior to initiation of psilocin administration, or may comprise a reference value derived from a population of subjects with ALS.

[0094] In some embodiments, maintenance or increase in NfL levels compared to a control indicates that the subject is not responding to administration of psilocin. In some embodiments, the administering may be ceased. Cessation of administration may allow for reassessment of the treatment approach or consideration of alternative therapeutic strategies. In some embodiments, maintenance of NIL levels refers to NIL concentrations that remain substantially unchanged from the control value over a defined monitoring interval. In some embodiments, an increase in NIL levels refers to NIL concentrations that exceed the control value by a defined threshold.

[0095] In some embodiments, the treatment period is extended for a duration of at least three months. A treatment duration of at least three months may correspond to standard evaluation intervals in clinical neurology trials for progressive motor disorders. During the treatment period, longitudinal improvements in NfL levels and ALSFRS-R scores may be monitored. In some embodiments, NfL levels may be measured at baseline and at regular intervals throughout the treatment period. In some embodiments, ALSFRS-R assessments may be performed at defined time points during treatment to track changes in motor function over time.

[0096] In some embodiments, longitudinal monitoring of NfL levels and ALSFRS-R scores may be used to adjust treatment parameters over time. Adaptive dosing based on individualized patient response may enable optimization of therapeutic regimens. In some embodiments, a reduction in NfL concentration compared to baseline, combined with stabilization or improvement in ALSFRS-R scores, may indicate therapeutic response. In some embodiments, treatment response may be defined as a statistically significant reduction in NfL concentration and / or stabilization or improvement in ALSFRS-R scores over a defined monitoring interval.

[0097] In various embodiments, the daily dose of psilocin induces less adverse effects compared to a standard control dose of psilocin. As used herein, the term "standard control dose" refers to a dose of psilocin or psilocybin that is administered in conventional psychedelic therapy protocols, which may produce perceptual disturbances, altered states of consciousness, or other psychoactive effects that impact daily functioning in a majority of treated individuals. In some embodiments, a standard control dose refers to doses of psilocybin or psilocin that exceed 10 mg per day or that are administered in single high-dose sessions for psychiatric indications.

[0098] As used herein, the term "adverse effects" refers to undesirable physiological or psychological responses associated with administration of psilocin or related compounds. Adverse effects may include, but are not limited to, gastrointestinal disturbances such as nausea and vomiting, perceptual disturbances, altered states of consciousness, anxiety, headache, cardiovascular changes, and other side effects that may impact tolerability or daily functioning.

[0099] In various embodiments, adverse effects are determined by a validated side effect scale. A validated side effect scale refers to a standardized assessment instrument that has been evaluated for reliability and validity in measuring the incidence, severity, and duration of side effects associated with pharmacological treatment. In some embodiments, a validated side effect scaleassesses the frequency and intensity of specific adverse events, including gastrointestinal symptoms, perceptual changes, mood alterations, and other treatment-related effects. In some embodiments, the daily dose of psilocin produces no more than mild transient side effects in at least 70% of subjects, as assessed by a validated side effect scale.

[0100] In some embodiments, psilocin provides reduced gastrointestinal side effects compared to psilocybin. Psilocybin undergoes dephosphorylation in the gut to form psilocin, and this gut-phase conversion process may contribute to gastrointestinal disturbances such as nausea and vomiting. Psilocin, as the pharmacologically active metabolite of psilocybin, bypasses gut-phase dephosphorylation when administered directly. By bypassing gut-phase dephosphorylation, psilocin may minimize nausea and vomiting that may otherwise occur with psilocybin administration.

[0101] In some embodiments, psilocin provides more predictable pharmacokinetics with reduced inter-individual variability compared to psilocybin. Psilocybin undergoes first-pass metabolism and conversion to psilocin, and variability in conversion efficiency among individuals may contribute to inter-individual variability in pharmacokinetic parameters and therapeutic response. Psilocin, as the pharmacologically active compound, avoids variability in first-pass metabolism and conversion efficiency, thereby providing more consistent plasma concentrations and pharmacological activity across subjects.

[0102] In various embodiments, psilocin exhibits a more rapid onset compared to psilocybin. The more rapid onset of psilocin may reduce the duration of psychoactive effects and may contribute to improved tolerability in subjects receiving daily dosing regimens.

[0103] In some embodiments, the method described herein further comprises a step before administering psilocin, comprising diagnosing a subject with ALS. Diagnostic confirmation of ALS may be performed using clinical and laboratory criteria in accordance with the revised El Escorial diagnostic criteria before initiating treatment. In some embodiments, the method comprises selecting a subject afflicted with ALS and administering low dose psilocin thereto.

[0104] In some embodiments, diagnostic confirmation of ALS includes electromyography (EMG). EMG may be used to assess electrical activity in muscles and detect abnormalities indicative of motor neuron dysfunction. In some embodiments, diagnostic confirmation of ALS includes magnetic resonance imaging (MRI). MRI may be used to exclude other conditions that may mimicALS and to visualize structural changes in the brain and spinal cord. In some embodiments, diagnostic confirmation of ALS includes biomarker evaluation of elevated neurofilament light chain (NfL) levels. As described above, NfL is a neuronal cytoskeletal protein that is released into blood or cerebrospinal fluid upon neuronal damage or degeneration. Elevated NfL levels may serve as a biochemical marker supporting an ALS diagnosis and may establish a reliable baseline for evaluating therapeutic response.

[0105] In some embodiments, the combination of clinical assessment, EMG, MRI, and biomarker evaluation provide diagnostic confirmation consistent with accepted standards for ALS diagnosis. Diagnostic benchmarks may help establish a reliable baseline for evaluating therapeutic response during treatment.

[0106] In some embodiments, patient selection involves defined inclusion and exclusion criteria. In some embodiments, the subject is not afflicted with schizophrenia, bipolar disorder, active substance use disorder, or any combination thereof. Exclusion of subjects with schizophrenia, bipolar disorder, or active substance use disorder may enhance safety and reduce the risk of adverse psychiatric events during treatment with psilocin.

[0107] In some embodiments, patient inclusion criteria comprise a confirmed diagnosis of ALS. In some embodiments, patient inclusion criteria further comprise an ALSFRS-R score meeting a defined threshold. The ALSFRS-R score may be used to assess baseline functional status and to identify subjects who may benefit from treatment.

[0108] In some embodiments, patient selection involves consideration of concurrent medication use. In some embodiments, the subject is not concurrently using a monoamine oxidase inhibitor (MAOI) or a selective serotonin reuptake inhibitor (SSRI).

[0109] As used herein, the term "monoamine oxidase inhibitor" or "MAOI" refers to a class of pharmaceutical compounds that inhibit the activity of monoamine oxidase enzymes. Monoamine oxidase enzymes are responsible for the metabolic breakdown of monoamine neurotransmitters, including serotonin, dopamine, and norepinephrine. MAOIs may increase synaptic concentrations of monoamine neurotransmitters by reducing their enzymatic degradation. Examples of MAOIs include, but are not limited to, phenelzine, tranylcypromine, isocarboxazid, and selegiline.

[0110] As used herein, the term "selective serotonin reuptake inhibitor" or "SSRI" refers to a class of pharmaceutical compounds that inhibit the reuptake of serotonin into presynaptic neurons. By blocking serotonin reuptake transporters, SSRIs may increase synaptic concentrations of serotonin. Examples of SSRIs include, but are not limited to, fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine.

[0111] Psilocin acts as an agonist at serotonin receptors, including the 5-HT2A receptor subtype, and may enhance serotonergic signaling in cortical and subcortical structures. Concurrent administration of psilocin with MAOIs or SSRIs may result in additive or synergistic effects on serotonergic neurotransmission. MAOIs may reduce the metabolic clearance of psilocin and other serotonergic compounds, thereby increasing systemic exposure and pharmacological activity. SSRIs may increase baseline synaptic serotonin concentrations, and concurrent administration of psilocin may further augment serotonergic activity.

[0112] Concurrent use of MAOIs or SSRIs with psilocin may increase the risk of excessive serotonergic stimulation. Excessive serotonergic stimulation may manifest as a constellation of symptoms that may include autonomic instability, neuromuscular abnormalities, and altered mental status. Autonomic symptoms may include hyperthermia, diaphoresis, tachycardia, and blood pressure fluctuations. Neuromuscular symptoms may include tremor, hyperreflexia, myoclonus, and muscle rigidity. Mental status changes may include agitation, confusion, and anxiety.

[0113] In some embodiments, exclusion of a subject concurrently using MAOIs or SSRIs reduces the risk of adverse serotonergic interactions during treatment with psilocin. In some embodiments, a subject is required to discontinue MAOI or SSRI therapy for a defined washout period prior to initiating psilocin administration. The duration of the washout period may depend on the pharmacokinetic properties of the specific MAOI or SSRI being discontinued, including the elimination half-life of the compound and any active metabolites.

[0114] In some embodiments, a subject who is not concurrently using MAOIs or SSRIs exhibits more predictable pharmacological responses to psilocin administration. The absence of concurrent serotonergic medications may allow for more consistent engagement of 5-HT2A receptors and TrkB receptors by psilocin without interference from altered baseline serotonergic tone or modified psilocin metabolism.

[0115] In some embodiments, psilocin is administered in a cyclical dosing regimen. Cyclical dosing regimens may comprise periods of administration followed by rest periods during which psilocin is not administered. In some embodiments, a cyclical dosing regimen comprises five days of administration followed by two days off. In some embodiments, a cyclical dosing regimen comprises four days of administration followed by three days off. Each possibility represents a separate embodiment of the invention.

[0116] In some embodiments, administering is before the night-time or night sleep of the subject.

[0117] In some embodiments, cyclical dosing regimens are repeated continuously over multiple treatment cycles. A treatment cycle may comprise a single period of administration followed by a single rest period. In some embodiments, cyclical dosing regimens are repeated indefinitely throughout the treatment period. Cyclical dosing regimens comprising rest periods may overcome potential tolerance of serotonin receptors to psilocin. Serotonin receptor tolerance may develop with continuous daily administration of serotonergic compounds, and periodic rest periods may allow for receptor re-sensitization.

[0118] In some embodiments, psilocin is administered in the evening, at night, or before sleep. In some embodiments, psilocin is administered within about 30 minutes to about 4 hours before the subject’s intended sleep period. Without wishing to be bound by theory, night-time administration may reduce the functional impact of transient perceptual, cognitive, autonomic, or psychoactive effects by aligning peak psilocin exposure with a period of reduced activity or sleep. In some embodiments, night-time administration is used to improve tolerability, reduce impairment of daily functioning, reduce daytime perceptual disturbances, or improve adherence to chronic or repeated dosing.

[0119] In some embodiments, night-time administration is combined with an enteric- coated, delayed-release, slow-release, or controlled-release formulation such that peak systemic exposure occurs during the subject’s sleep period or during a low-activity period.

[0120] In some embodiments, psilocin dosing follows a titrated dose escalation protocol. Titrated dose escalation may involve initiating treatment at a lower dose and gradually increasing the dose over time. In some embodiments, psilocin dosing is initiated at a dose ranging between 0.01 mg and 2 mg per day. In some embodiments, the initial dose is ranging between 0.05 and 2 mg perday. In some embodiments, the initial dose is 0.2 mg per day. Each possibility represents a separate embodiment of the invention.

[0121] According to another aspect, there is provided a method for ameliorating at least one symptom of ALS in a subject afflicted therewith, the method comprising the steps: (a) orally administering to the subject psilocin at a daily dose ranging between 0.01 mg and 10 mg; (b) monitoring the subject; and (c) adjusting the daily dose based on the results of the monitoring.

[0122] In some embodiments, monitoring comprises determining the appearance or increased incidence of at least one side effect or adverse effect in the subject.

[0123] In some embodiments, the at least one side effect or adverse effect is selected from: suicidal ideation, cardiovascular manifestation, hallucination, impaired daily ability to operate, serotonin syndrome, or any combination thereof.

[0124] The terms “side effect” and “adverse effect” are used herein interchangeably.

[0125] In some embodiments, monitoring for suicidality is performed using the Columbia-Suicide Severity Rating Scale (C-SSRS). As used herein, the term “Columbia-Suicide Severity Rating Scale” or “C-SSRS” refers to a validated clinical assessment instrument used to evaluate suicidal ideation and suicidal behavior. In some embodiments, monitoring may comprise assessing the absence of emergent suicidal ideation (SI) or suicidal behavior (SB) compared to baseline. In some embodiments, treatment may be held or ceased if emergent suicidal ideation or suicidal behavior is detected compared to baseline. Each possibility represents a separate embodiment of the invention.

[0126] In some embodiments, monitoring for cardiovascular manifestations is performed. As used herein, the term “cardiovascular manifestation” refers to changes in cardiovascular parameters deviating from normal / standard / healthy control or condition, including, but not limited to, increased blood pressure, increased heart rate, or both, such as measured under rest conditions. In some embodiments, monitoring comprises measuring systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), or any combination thereof. In some embodiments, monitoring performed using smartwatch-based digital metrics, including heart rate variability monitoring. In some embodiments, treatment is held or ceased if SBP is greater than or equal to 180 mmHg. In some embodiments, treatment is held or ceased if DBP is greater than or equal to110 mmHg. In some embodiments, treatment is held or ceased if HR is greater than or equal to 130 beats per minute (bpm) at rest. Each possibility represents a separate embodiment of the invention. In some embodiments, monitoring cardiovascular manifestation is performed under rest conditions (of the subject). In some embodiments, monitoring cardiovascular manifestation is performed when the subject is resting or in a resting subject.

[0127] In some embodiments, cardiovascular monitoring cut-offs fall within defined subranges. In some embodiments, treatment is held if SBP ranges from 160 mmHg to 179 mmHg. In some embodiments, treatment is held if DBP ranges from 100 mmHg to 109 mmHg. In some embodiments, treatment is held if HR ranges from 110 bpm to 129 bpm at rest. In some embodiments, treatment is ceased if SBP is greater than or equal to 180 mmHg, DBP is greater than or equal to 110 mmHg, or HR is greater than or equal to 130 bpm at rest. Each possibility represents a separate embodiment of the invention.

[0128] In some embodiments, monitoring for impact on cognition is performed. In some embodiments, monitoring comprises administering the Digit Symbol Substitution Test (DSST). As used herein, the term “Digit Symbol Substitution Test” or “DSST” refers to a validated neuropsychological assessment that measures cognitive processing speed, attention, and executive function. In some embodiments, monitoring comprises administering the Psychomotor Vigilance Test (PVT). As used herein, the term “Psychomotor Vigilance Test” or “PVT” refers to a validated assessment that measures sustained attention and reaction time. In some embodiments, a decline in DSST or PVT performance compared to baseline indicates impaired daily ability to operate. Each possibility represents a separate embodiment of the invention.

[0129] In some embodiments, monitoring for psychedelic effects is performed. In some embodiments, monitoring comprises administering the Mystical Experience Questionnaire (MEQ-30). As used herein, the term “Mystical Experience Questionnaire” or “MEQ-30” refers to a validated 30-item questionnaire used to assess the occurrence and intensity of mystical-type experiences. In some embodiments, a “complete mystical experience” is defined as a score of greater than or equal to 60% across all domains of the MEQ-30. In some embodiments, monitoring comprises assessing Drug-Liking Visual Analog Scale (VAS) scores. In some embodiments, a complete mystical experience or sustained Drug-Liking VAS elevation suggesting psychedeliceffect indicates that treatment should be held pending review. Each possibility represents a separate embodiment of the invention.

[0130] In some embodiments, monitoring for seizures is performed. In some embodiments, a new unprovoked seizure not due to an acute reversible cause indicates that treatment should be ceased. As used herein, the term “unprovoked seizure” refers to a seizure occurring in the absence of an identifiable acute precipitating factor such as metabolic disturbance, acute intoxication, or acute withdrawal.

[0131] In some embodiments, monitoring for serotonin syndrome is performed. As used herein, the term “serotonin syndrome” refers to a potentially life-threatening condition resulting from excessive serotonergic activity, characterized by a constellation of symptoms including autonomic instability, neuromuscular abnormalities, and altered mental status. In some embodiments, serotonin syndrome is diagnosed using the Hunter criteria. As used herein, the term “Hunter criteria” refers to a validated clinical decision rule for diagnosing serotonin syndrome based on the presence of specific clinical findings including clonus, agitation, diaphoresis, tremor, and hyperreflexia. In some embodiments, suspected serotonin syndrome as determined by the Hunter criteria indicates that treatment should be ceased. Each possibility represents a separate embodiment of the invention.

[0132] In some embodiments, a responsive subject is defined as such that manifests amelioration of at least one symptom associated with the disease as disclosed herein, e.g., ALS, or a neurodegenerative disease, and does not manifest a side / adverse effect or a combination thereof.

[0133] In some embodiments, an adversely responsive subject is defined as such that manifests a side / adverse effect or a combination thereof. In some embodiments, an adversely responsive subject does or does not manifest amelioration of at least one symptom associated with the disease as disclosed herein, e.g., ALS, or a neurodegenerative disease.

[0134] In some embodiments, the monitoring comprises determining at least one of: NfL levels, motor function assessment using the ALSFRS-R, or both, in the subject or a sample obtained or derived therefrom.

[0135] In some embodiments, adjusting comprises increasing or decreasing. In some embodiments, increasing comprises enhancing. In some embodiments, decreasing comprises reducing. In some embodiments, adjusting is titrating.

[0136] In some embodiments, a reduction in the levels of NfL compared to a control, indicates that the subject is responding to the administering, and the method further comprises repeating or repeatedly administering psilocin to the subject. In some embodiments, repeating or the repeatedly administering comprises repeatedly administering the same dose of psilocin or a reduced dose of psilocin.

[0137] In some embodiments, maintenance (e.g., unchanged) or increase in the levels of NfL compared to a control, indicates that the subject is not responding to the administering, and the method further comprises decreasing the dose of psilocin or ceasing the administering.

[0138] In some embodiments, increasing (or enhancing) or decreasing (or reducing) the dose of psilocin (based on the monitoring) is compared to the dose administered thus far according to the method of the invention, up until the determination according to the monitoring step.

[0139] In some embodiments, the psilocin dose is gradually increased by 0.01 mg to 2 mg weekly. In some embodiments, the dose is increased by 0.05 to 1.5 mg weekly. In some embodiments, the dose is increased by 0.75 to 2.0 mg weekly. In some embodiments, the dose is increased by 0.01-3 mg weekly. Each possibility represents a separate embodiment of the invention.

[0140] In some embodiments, titration increments may fall within defined subranges. In some embodiments, the titration increment ranges from 0.05 mg to 1 mg. In some embodiments, the titration increment ranges from 0.1 mg to 1.5 mg. In some embodiments, the titration increment ranges from 0.15 mg to 2 mg. Each possibility represents a separate embodiment of the invention.

[0141] In various embodiments, titrated dose escalation may continue until a ceiling dose is reached. In some embodiments, the ceiling dose is 10 mg per day. Gradual titration may mitigate adverse effects and may promote therapeutic tolerance in subjects receiving psilocin for treatment of ALS.

[0142] In some embodiments, cyclical dosing regimens and titrated dose escalation protocols are combined. For example, a subject may receive psilocin according to a cyclical regimen comprising five days of administration followed by two days off, with the daily dose during administrationperiods initiated at 0.01 mg to 3 mg and increased by 0.01 mg to 3 mg weekly until a ceiling dose of 10 mg per day is reached. In some embodiments, a subject receives psilocin according to a cyclical regimen comprising four days of administration followed by three days off, with titrated dose escalation as described above. Each combination represents a separate embodiment.

[0143] A number of implementations have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the disclosure. Accordingly, other implementations are within the scope of the following claims.

[0144] Any concentration ranges, percentage range, or ratio range recited herein are to be understood to include concentrations, percentages or ratios of any integer within that range and fractions thereof, such as one tenth and one hundredth of an integer, unless otherwise indicated.

[0145] Any number range recited herein relating to any physical feature, such as polymer subunits, size or thickness, are to be understood to include any integer within the recited range, unless otherwise indicated.

[0146] As used herein, the terms “subject” or “individual” or “animal” or “patient” or “mammal,” refers to any subject, particularly a mammalian subject, for whom therapy is desired, for example, a human.

[0147] In the discussion unless otherwise stated, adjectives such as “substantially” and “about” modifying a condition or relationship characteristic of a feature or features of an embodiment of the invention, are understood to mean that the condition or characteristic is defined to within tolerances that are acceptable for operation of the embodiment for an application for which it is intended. Unless otherwise indicated, the word “or” in the specification and claims is considered to be the inclusive “or” rather than the exclusive or, and indicates at least one of, or any combination of items it conjoins.

[0148] It should be understood that the terms “a” and “an” as used above and elsewhere herein refer to “one or more” of the enumerated components. It will be clear to one of ordinary skill in the art that the use of the singular includes the plural unless specifically stated otherwise. Therefore, the terms “a”, “an” and “at least one” are used interchangeably in this application.

[0149] For purposes of better understanding the present teachings and in no way limiting the scope of the teachings, unless otherwise indicated, all numbers expressing quantities, percentages or proportions, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0150] In the description and claims of the present application, each of the verbs, “comprise”, “include”, and “have” and conjugates thereof, are used to indicate that the object or objects of the verb are not necessarily a complete listing of components, elements or parts of the subject or subjects of the verb.

[0151] Other terms as used herein are meant to be defined by their well-known meanings in the art.

[0152] Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting. Additionally, each of the various embodiments and embodiments of the present invention as delineated hereinabove and as claimed in the claims section below finds experimental support in the following examples.

[0153] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.EXAMPLESMaterials and MethodsTest System

[0154] Zebrafish is an emerging model for high-throughput neurobehavioral studies since the basic structure of the central nervous system has all the major domains found in the mammalian brain and they produce the same neurotransmitters, such as glutamate, Gamma-Aminobutyric Acid (GABA), serotonin, dopamine, histamine, and acetylcholine. The zebrafish motor system also has some similarities to humans, and larvae from 4-5 days post fertilization (dpf) already show a large number of neurobehavioral phenotypes, making it a relevant model to study motor neuron diseases.

[0155] The overexpression of mutant but not wild-type human superoxide dismutase 1 (SOD1) has been shown to lead to short motor axons with early branching associated with deficient swimming in response to touch. Tg(SOD(G93R)OS10:hs:dsRed) zebrafish which carry the human mutation (G93R) of SOD1 linked to ALS, express DsRed protein under the hsp70 promoter. This mutation induces high oxidative stress levels in the neurons activating the hsp70 promoter, increasing the DsRed expression and serving as a quantifiable readout of cellular stress level. Test Item Preparation

[0156] Psilocin (CAS 520-53-6) was evaluated as a test item in this study. On the day of exposure, the test item was freshly dissolved at 10 mM in MilliQ water supplemented with 1% ascorbic acid. From this stock, serial dilutions were prepared in MilliQ water supplemented with ascorbic acid to obtain 100 working solutions for each treatment group and 1% ascorbic acid. The remaining stock solution was aliquoted and stored light-protected at -80±10 °C for further use throughout the study, while remaining working solutions were discarded.Experimental Groups

[0157] Sample size: 24 Sodl(G93R) larvae (DsRed+) per experimental groups G2-G5 and Sodl(WT) larvae (DsRed-) for G1. DsRed+ Sodl(G93R) larvae were treated with psilocin at three concentrations (G3-G5) per trial. In Trial 1, concentrations of 0.1, 0.2, and 20 pM were tested. As an unaffected control (Gl), a group of DsRed- Sodl(WT) larvae was vehicle-treated (ascorbic acid at 0.01% in water). As disease model control (G2), DsRed+ Sodl(G93R) larvae were vehicle-treated.Treatment Protocol

[0158] Embryos from the ALS zebrafish transgenic model carrying the Sodl(G93R) mutation, as well as Sodl(WT) embryos as negative control for the mutation were obtained. Synchronized embryos were supplied to the laboratory and kept in the incubator at 28.5±0.5 °C under cycles of 14 h Light - 10 h Darkness. At 2 dpf, larvae were sorted under the stereomicroscope by their fluorescence patterns into DsRed+ (heterozygous and homozygous affected larvae) and DsRed-(unaffected larvae) and individually dispensed in 96-square well plates with flat bottom together with 400 pL of E3+HEPES medium.

[0159] Plates returned to the incubator at 28.5±0.5 °C under 14 h Light - 10 h Darkness cycles until 5 dpf, when these larvae were used for the motor-behavior analysis.Motor Behavior Assessment

[0160] At 5 dpf, the larvae in the 96-square-well plate were introduced in the DanioVision observation chamber (Noldus) and kept under light at 28±0.5°C during 20 min for their acclimation to the recording conditions. Then, larvae were individually tracked under alternating light (L) and dark (D) phases of 10 min each. Multiple locomotor parameters, including total distance moved, mean velocity during movement, maximum velocity, moving duration and frequency, and distance moved at high velocities were analyzed using EthoVision software (Noldus). Once the tracking was concluded, the larvae were evaluated under the stereoscope. Dead larvae or larvae that presented any malformation that could alter the locomotion (including mortality, edemas, head, trunk, or swim bladder alterations) were registered and discarded from the data analysis.Statistical Analysis

[0161] Raw data regarding larvae locomotor activity was first analyzed by Ethovision XT software to obtain each parameter (distance moved, mean velocity while moving, maximum velocity, moving duration and frequency, and distance moved at high velocities) by individual larva in 10-min time-bins, i.e., light phase and dark phase. The data of each variable described above were statistically compared between experimental groups by Kruskal-Wallis test followed by Dunn's test within each lighting phase. Experimental groups with less than 12 healthy larvae (50%) were discarded from the data analysis. Thus, each locomotor parameter in the vehicle -treated Sodl(G93R) larvae (G2) was compared against Sodl(WT) larvae (Gl) to confirm the diseasemodel phenotype. Besides, treated experimental groups (G3-G5) were compared against the vehicle-treated disease model (G2) to evaluate the efficacy of the test item on the motor-behavior altered by the disease. If an effect of psilocin was observed on the disease phenotype, the experimental group was compared with the unaffected control group (Gl) to evaluate the magnitude or the betterment.Results Summary

[0162] In zebrafish models of ALS, increased locomotor activity (hyperlocomotion) is commonly observed during early developmental stages and is suggested to reflect early motor neuron hyperexcitability that precedes overt neurodegeneration.Mean Velocity While Moving (Fig. 1 )

[0163] The disease phenotype of the locomotor activity was evidenced by the increased mean velocity while moving of the Sodl(G93R) larvae (G2) when compared with the unaffected SodltWT) larvae (Gl) during the light phase (p<0.01). At this phase, the Sodl(G93R) larvae treated with psilocin at 0.1 pM (G3) reduced the mean velocity while moving with respect to the disease model (p<0.05), reaching similar values to those shown in the unaffected Sodl(WT) larvae (Gl) (p>0.05). No disease phenotype was observed in the mean velocity during the dark phase (p>0.05, G2 vs. Gl).Maximum Velocity (Fig. 2)

[0164] Sodl(G93R) larvae (G2) showed a tendency to increase the maximum velocity with respect to the Sodl(WT) larvae (Gl) during the dark phase (p=0.07). When applying psilocin to Sodl(G93R) larvae, the maximum velocity differed from the disease model (G2) at 0.1 and 0.2 pM (p<0.001) and at 20 pM (p<0.05), reaching the maximum velocity showed by the Sodl(WT) larvae (Gl, p>0.05).

[0165] Further to the above, in a pilot study conducted in rodents, it was demonstrated that the psilocin was 10 times more potent than expected, with 5 - HT2A engagement at 0.03 mg, where the state of the art relates to 3 mg as a borderline engagement level.Discussion

[0166] Altogether, an effect of psilocin on the mean velocity while moving was observed at 0.1 pM, reverting the locomotor anomaly displayed by Sodl(G93R) larvae during the light phase.Additionally, psilocin at 0.1-20 pM reverted the tendency of Sodl(G93R) larvae increasing the maximum velocity in the dark phase.

[0167] In the Sodl(G93R) ALS model, psilocin modestly modulated motor behavior at low concentrations, improving specific locomotor parameters. At 0.1 pM, psilocin significantly improved the mean velocity while moving during the light phase, reversing a disease-associated locomotor abnormality and normalizing performance toward unaffected control larvae. In addition, psilocin across multiple concentrations attenuated the abnormal upward tendency in the maximum velocity observed during the dark phase.

[0168] Taken together, these results suggest a narrow, and possibly non-linear, dose-response between psilocin and the modulation of motor behavior in an in vivo ALS model, with detectable activity primarily around 0.1 pM. The selective behavioral effects observed suggest that psilocin may act primarily via neuronal network or neurotransmitter-modulation, rather than direct cellular neuroprotection. The lack of increasing efficacy at higher concentrations may fit with a non-linear (e.g. inverted U-shaped) dose-response, potentially reflecting engagement of additional pharmacological targets, non-specific central nervous system (CNS) effects that counteract beneficial neuromodulation, or target saturation.

[0169] The finding that low-dose psilocin (0.1 pM) was effective while higher doses showed diminishing or no additional benefit was unexpected and supports the claimed low-dose therapeutic approach. This observation suggests an optimal therapeutic window at low concentrations, which may have implications for dosing strategies in clinical applications.

[0170] The reversal of hyperlocomotion, a marker of motor neuron hyperexcitability in the Sodl(G93R) model, supports disease-relevant modulation rather than merely symptomatic treatment. By normalizing locomotor parameters toward those of unaffected control larvae, psilocin may address underlying pathophysiological mechanisms associated with ALS progression.

[0171] The efficacy observed at sub-psychoactive concentrations suggests that therapeutic benefit may be achieved with reduced likelihood perceptual disturbances associated with standard psychedelic doses. This finding supports the use of low-dose psilocin formulations that may be better tolerated in patient populations requiring daily administration.

[0172] The data supports the claimed dose range of 0.01-10 mg daily by demonstrating that low concentrations are therapeutically active in an established ALS model. The zebrafish Sodl(G93R) model recapitulates key features of human ALS pathophysiology, and the observed effects at low psilocin concentrations provide a rationale for the claimed dosing regimen.

[0173] The non-linear dose-response relationship was unexpected and suggests an optimal therapeutic window at low doses. The lack of increasing efficacy at higher concentrations, combined with the significant effects observed at 0.1 pM, indicates that lower doses may be preferable for achieving therapeutic outcomes while minimizing potential adverse effects associated with higher exposures.iPSC Functional Assay

[0174] A functional study is performed to evaluate low-dose psilocin in a human amyotrophic lateral sclerosis (ALS) cellular model using patient-derived induced pluripotent stem cell (iPSC)-derived spinal motor neurons carrying ALS-associated genetic mutations and / or sporadic ALS phenotypes. Cells may be provided as pre-differentiated cryopreserved motor neurons and cultured under standard neuronal assay conditions in multi-well plate formats for approximately 14-21 days, with psilocin administered chronically across a defined concentration range through repeated media exchange.

[0175] The primary functional assay includes microelectrode array (MEA) analysis to assess spontaneous neuronal network activity, including firing rate, burst activity, and disease-associated neuronal hyperexcitability. The objective is to determine whether psilocin normalizes abnormal electrophysiological activity in ALS-derived motor neurons. Additional readouts may include cellular viability assays to assess neuroprotection, inflammatory biomarkers including IL-6 or related cytokines to assess neuroinflammatory signaling, and glutamate measurements to assess excitotoxic stress,

[0176] A positive response is expected and may comprise approximately 20-30% normalization of abnormal neuronal firing activity relative to disease baseline, improved neuronal viability relative to vehicle-treated controls, and reductions in inflammatory and excitotoxic biomarkers.

[0177] This study is used to identify a therapeutically effective concentration range of psilocin in human ALS-relevant neurons, support translational dose selection, and demonstrate modulation ofneuronal hyperexcitability, neuroprotection, inflammation, excitotoxic stress, and pathological protein mislocalization associated with ALS.

[0178] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.

Claims

1. CLAIMS1. A method for ameliorating at least one symptom of Amyotrophic Lateral Sclerosis (ALS) in a subject afflicted therewith, the method comprising orally administering to said subject psilocin at a daily dose ranging between 0.01 mg and 10 mg.

2. The method of claim 1, wherein the psilocin is in a composition further comprising a pharmaceutically acceptable carrier.

3. The method of claim 1 or 2, wherein said psilocin is formulated using a stabilization technique selected from the group consisting of: encapsulation, co-formulation with an antioxidant, or both.

4. The method of claim 3, wherein said antioxidant comprises ascorbic acid, ethylenediaminetetraacetic acid (EDTA), N-acetylcysteine (NAC), glutathione, cysteine, sodium metabisulfite, sodium bisulfite, tocopherol, butylated hydroxytoluene, butylated hydroxyanisole, or any combination thereof.

5. The method of any one of claims 1 to 4, further comprising a step comprising monitoring said subject after said administering.

6. The method of claim 5, wherein said monitoring comprises determining appearance of at least one side effect selected from the group consisting of: Suicidal ideation, cardiovascular manifestation, hallucination, impaired daily ability to operate, serotonin syndrome, and any combination thereof.

7. The method of claim 6, wherein lack of appearance of said at least one side effect indicates that said subject is responding to said administering, thereby repeating said administering.

8. The method of claim 7, wherein said repeating comprises repeatedly administering said dose of psilocin or an increased dose of said psilocin.

9. The method of claim 6, wherein appearance of said at least one side effect indicates that said subject is adversely responding to said administering, thereby reducing the dose of said psilocin or ceasing said administering.

10. The method of any one of claims 1 to 9, wherein said daily dose of said psilocin induces less adverse effects compared to a standard control dose of psilocin.

11. The method of claim 10, wherein said adverse effects are determined by a validated side effect scale.

12. The method of any one of claims 1 to 11, further comprising a step before said administering, comprising diagnosing said subject with ALS.

13. The method of any one of claims 1 to 12, wherein said subject is not afflicted with schizophrenia, bipolar disorder, active substance use disorder, or any combination thereof.

14. The method of any one of claims 1 to 13, wherein the subject is not concurrently using a monoamine oxidase inhibitor (MAOI) or a selective serotonin reuptake inhibitor (SSRI).

15. The method of any one of claims 2 to 14, wherein said composition further comprises an enteric coat.

16. The method of claim 15, wherein said psilocin is encapsulated within said enteric coat.

17. The method of claim 15 or 16, wherein said composition is formulated for controlled release.

18. The method of claim 17, wherein said controlled release is pH-controlled release.

19. The method of any one of claims 5 to 18, wherein said monitoring further comprises determining at least one of: neurofilament light chain (NfL) levels, motor function assessment using the ALS Functional Rating Scale-Revised (ALSFRS-R), or both, in said subject or a in sample obtained or derived therefrom.

20. The method of claim 19, wherein a reduction in said levels of said NfL compared to a control, indicates that said subject is responding to said administering, thereby repeating said administering.

21. The method of claim 19, wherein maintenance or increase in said levels of said NfL compared to a control, indicates that said subject is not responding to said administering, thereby ceasing said administering.

22. A method for ameliorating at least one symptom of ALS in a subject afflicted therewith, the method comprising the steps: (a) orally administering to said subject psilocin at a daily dose ranging between 0.01 mg and 10 mg; (b) monitoring appearance of at least one side effect selected from the group consisting of: suicidal ideation, cardiovascular manifestation, hallucination, impaired daily ability to operate, serotonin syndrome, and any combination thereof; and (c) adjusting said daily dose based on the results of said monitoring.

23. The method of claim 22, wherein said adjusting is increasing or decreasing.

24. The method of claim 22 or 23, wherein lack of appearance of said at least one side effect indicates that said subject is responding to said administering, thereby repeating said administering.

25. The method of claim 24, wherein said repeating comprises repeatedly administering said dose of psilocin or an increased dose of said psilocin.

26. The method of claim 22 or 23, wherein appearance of said at least one side effect indicates that said subject is adversely responding to said administering, thereby reducing the dose of said psilocin or ceasing said administering.

27. The method of any one of claims 22 to 26, wherein said monitoring further comprises determining at least one of: NfL levels, motor function assessment using the ALSFRS-R, or both, in said subject or a in sample obtained or derived therefrom.

28. The method of claim 27, wherein a reduction in said levels of said NfL compared to a control, indicates that said subject is responding to said administering, thereby repeating said administering.

29. The method of claim 27, wherein maintenance or increase in said levels of said NfL compared to a control, indicates that said subject is not responding to said administering, thereby ceasing said administering.

30. An oral pharmaceutical composition comprising psilocin for use at a daily dose ranging between 0.01 mg and 10 mg of psilocin in the amelioration of at least one symptom of ALS in a subject afflicted therewith.

31. The oral pharmaceutical composition of claim 30, further comprising at least one stabilizing agent selected from the group consisting of: an antioxidant, an oxygen scavenger, a moisture-absorbing agent, and any combination thereof.

32. The oral pharmaceutical composition of claim 30 or 31 , being in a form selected from the group consisting of: a tablet, a capsule, a suspension, a sublingual film, a buccal film, and a spray.

33. The oral pharmaceutical composition of any one of claims 30 to 31, further comprising a carrier selected from the group consisting of: cyclodextrin, lipid nanoparticle, phospholipid vesicle, and lecithin-based emulsion.

34. The oral pharmaceutical composition of claim 30, further comprising an enteric coat.

35. The oral pharmaceutical composition of claim 34, wherein said psilocin is encapsulated within said enteric coat.

36. The oral pharmaceutical composition of claim 34 or 35, wherein said composition is formulated for controlled release.

37. The oral pharmaceutical composition of claim 36, wherein said controlled release is pH-controlled release.

38. The oral pharmaceutical composition of any one of claims 30 to 37, characterized by being stable for at least six months at room temperature.